Carregant...
Tipus de document
Treball de fi de grauData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/112374
Personalised medicine of Cystic fibrosis
Títol de la revista
Autors
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
[en] The European commission defines personalised medicine as a medical approach that uses molecular insights into health and disease brought on by the sequencing of the genome to guide decision-making with regard to the prediction, prevention, diagnosis and treatment of illnesses. Its main aim is generally perceived to be “the right treatment for the right person at the right time”.
This new approach to medicine attracted worldwide attention in 2012 when president Obama launched a research project with the objective to implement personalised medicine principles in America. On his speech, he used Ivacaftor as an example of the potential of personalised medicine. The importance of Ivacaftor development lays on the fact that it’s the first drug capable of treating cystic fibrosis aetiology rather than its symptoms in a specific subset of mutations.
Given the impact Ivacaftor had in the media and that cystic fibrosis is not sufficiently known in our society, the objective of this project is to try to understand the underlying mechanisms of cystic fibrosis disease and shed light on what makes Ivacaftor a remarkable advancement in cystic fibrosis therapy and personalised medicine.
Descripció
Treballs Finals de Grau de Farmàcia, Facultat de Farmàcia, Universitat de Barcelona, 2017. Tutor: Carlos Julián Ciudad i Gómez
Matèries (anglès)
Citació
Col·leccions
Citació
CABRÉ JUAN, Antoni. Personalised medicine of Cystic fibrosis. [consulta: 14 de desembre de 2025]. [Disponible a: https://hdl.handle.net/2445/112374]